Envestnet Portfolio Solutions Inc. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 37.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,358 shares of the medical instruments supplier's stock after selling 10,999 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Becton, Dickinson and Company were worth $4,205,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $6,406,000. Ritholtz Wealth Management acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $224,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Becton, Dickinson and Company by 1.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 8,047 shares of the medical instruments supplier's stock worth $1,843,000 after buying an additional 79 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Becton, Dickinson and Company Price Performance
Shares of BDX stock traded down $0.53 during trading hours on Wednesday, hitting $171.04. The company's stock had a trading volume of 2,118,097 shares, compared to its average volume of 2,025,125. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The business has a fifty day moving average of $178.25 and a 200-day moving average of $210.49. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a market cap of $49.02 billion, a price-to-earnings ratio of 32.64, a P/E/G ratio of 1.30 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the company earned $3.17 earnings per share. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.43%. Becton, Dickinson and Company's payout ratio is currently 79.39%.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target on the stock. in a research note on Thursday, May 1st. Stifel Nicolaus reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $219.22.
Read Our Latest Analysis on BDX
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. The trade was a 8.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now owns 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
